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Neonatal infection with Streptococcus agalactiae (group B Streptococcus [GBS]) is a leading cause of sepsis and meningitis in
newborns. Recent guidelines have recommended universal screening of all pregnant women to identify those colonized with
GBS and administration of peripartum prophylaxis to those identified as carriers to reduce the risk of early-onset GBS disease in
neonates. Enriched culture methods are the current standard for prenatal GBS screening; however, the implementation of more
sensitive molecular diagnostic tests may be able to further reduce the risk of early-onset GBS infection. We report a clinical eval-
uation of the Xpert GBS LB assay, a molecular diagnostic test for the identification of GBS from broth-enriched vaginal/rectal
specimens obtained during routine prenatal screening. A total of 826 specimens were collected fromwomen undergoing prena-
tal screening (35 to 37 weeks’ gestation) and tested at one of three clinical centers. Each swab specimen was tested directly prior
to enrichment using the Xpert GBS assay. Following 18 to 24 h of broth enrichment, each specimen was tested using the Xpert
GBS LB assay and the FDA-cleared Smart GBS assay as a molecular diagnostic comparator. Results obtained using all three mo-
lecular tests were compared to those for broth-enriched culture as the gold standard. The sensitivity and specificity of the Xpert
GBS LB assay were 99.0% and 92.4%, respectively, compared to those for the gold standard culture. The Smart GBSmolecular
test demonstrated sensitivity and specificity of 96.8% and 95.5%, respectively. The sensitivities of the two broth-enrichedmolec-
ular methods were superior to those for direct testing of specimens using the Xpert GBS assay, which demonstrated sensitivity
and specificity of 85.7% and 96.2%, respectively.
Streptococcus agalactiae (group B Streptococcus [GBS]) is aGram-positive bacterium associated with transient coloniza-
tion of mucosal membranes throughout the body, including the
vagina, gastrointestinal tract, and urethra (1). GBS rarely causes
disease in healthy individuals but can cause serious illness in im-
munocompromised patients, elderly individuals, and newborn
infants (2). Of particular concern is neonatal infection caused by
vertical transmission during labor and birthing. Transmission
from an asymptomatically colonized mother to the neonate can
result in early-onset invasive GBS disease, which is a leading cause
of sepsis and meningitis in newborns in the United States (3).
Early-onset GBS disease in newborns can result in death or long-
term disabilities such as mental retardation and hearing or vision
loss (4). Because these infections are acquired through direct con-
tact of the neonate with GBS in the mother’s urogenital tract dur-
ing delivery, it has become a universal practice to screen pregnant
women for vaginal/rectal colonization with GBS at 35 to 37 weeks’
gestation (5). The identification of GBS during routine screening
results in administration of intrapartum prophylaxis to mitigate
transmission of bacteria and reduce the chance of invasive disease
in the newborn if GBS is transmitted vertically during the birthing
process. The implementation of this screening and prophylaxis
strategy has been very successful, reducing the incidence of early-
onset GBS by 60 to 86% (6).
Routine culture-based screening methods rely on the collec-
tion of a vaginal/rectal swab specimen, which is then enriched
using a selective broth medium such as LIM broth to achieve op-
timal sensitivity. Following enrichment, the specimen is subcul-
tured onto blood agar plates (BAP) where presumptive GBS col-
onies are identified visually by characteristic zones of narrow
beta-hemolysis. The identification of the presumptive colonies is
confirmed using phenotypic and biochemical methods (5). A lim-
itation to this method is that approximately 5 to 8% percent of all
GBS isolates do not produce -hemolysin (7–9). The lack of char-
acteristic hemolysis in these strains can lead to a false-negative
culture result (9). Alternative screening media, including chromo-
genic Granada agar, have been validated for identification of GBS.
The GBS colonies grown on Granada agar produce an orange
carotenoid pigment (granadaene), which allows easy identifica-
tion of GBS colonies. While this test is more sensitive than subcul-
ture to blood agar, most non-hemolytic GBS strains also fail to
produce granadaene (9). A failure to identify granadaene-negative
and nonhemolytic strains may result in up to 5% of colonized
women not receiving appropriate prophylaxis. Finally, culture-
based screening methods require broth enrichment for optimal
sensitivity. This extends the turnaround time (TAT) for results to
48 to 72 h. Because screening cultures are collected at 35 to 37
weeks’ gestation, this delay does not typically impact patient man-
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agement. However, up to 15% of pregnant women do not receive
adequate prenatal care including routine screening for GBS (10,
11). In these cases, a more rapid and sensitive direct testing
method for screening may be desirable.
We conducted a multicenter evaluation of the FDA-cleared
Xpert GBS LB assay (Cepheid, Sunnyvale, CA) for detection of
GBS from broth-enriched vaginal/rectal swabs. This test utilizes
real-time PCR to detect a conserved target within the 3= DNA
region adjacent to cfb, the gene encoding the S. agalactiae CAMP
factor (12–14). Results were compared to LIM broth-enriched
culture with plating on 5% sheep blood agar as a gold standard.
The sensitivity and specificity of the Xpert GBS LB assay were also
compared to those of a second molecular test, the Smart GBS
(Cepheid), conducted on broth-enriched specimens, and to those
of direct analysis of nonenriched swab specimens using the Xpert
GBS assay (Cepheid).
MATERIALS AND METHODS
Collection of vaginal and/or rectal specimens. Two paired vaginal/rectal
swabs were collected from patients at 35 to 37 weeks of gestation under-
going routine GBS screening. A total of 861 specimens were collected and
tested at 3 separate trial sites (The Medical College of Wisconsin, Indiana
University School of Medicine, and Sacred Heart Hospital) in accordance
with site-specific institutional review board (IRB)-approved protocols.
Only one set of swabs per patient was tested to avoid duplicate results. One
of the two swabs was removed from the transport medium and used to test
direct specimens on the Xpert GBS assay prior to LIM broth enrichment.
The second swab was used for inoculation of LIM broth for specimen
enrichment. After 24 h of enrichment, the LIM broth was used to test in
parallel the Xpert GBS LB and Smart GBS assays and reference cultures.
The collection and use of clinical specimens for this study were approved
by the IRB at each participating clinical center.
Xpert GBS assay and Xpert GBS LB assay. One of two paired rectal/
vaginal swab specimens was transferred to the designated chamber of the
Xpert GBS assay cartridge. The swab was snapped at the score mark, and
the cartridge was loaded into a Cepheid GeneXpert system (GeneXpert
IV, GeneXpert XVI, Infinity 48, or Infinity 80 system) for automated
sample preparation and PCR. The results for specimens are reported as
positive or negative based on the detection of a genomic target sequence
adjacent to the S. agalactiae cfb gene. The total assay run time was 55 min
with1 min of hands-on time. Specimens with tests that yielded invalid
results were retested once by transferring the remaining fluid in the load-
ing chamber to a new cartridge. If no fluid remained in the invalid car-
tridge, the swab was transferred to a new cartridge, using sterile tweezers,
and a single repeat test was performed. The second paired swab was used
to inoculate LIM broth for culture enrichment. A sterile swab (provided
by Cepheid) was dipped into the broth-enriched culture and then trans-
ferred to a designated chamber and was processed the same as the direct
method. The positive and negative controls were run on each day of test-
ing for the clinical study; however, once verified by a clinical laboratory,
controls may be reduced in frequency according to the College of Amer-
ican Pathologists (CAP) guidelines for single-use assays with internal con-
trols (once every 30 days or once every new lot of cartridges is tested).
Smart GBS assay. A 200-l aliquot of each LIM broth-enriched spec-
imen was transferred to a lysis tube (provided), mixed, and centrifuged at
10,000 g for 3 min. The supernatant was removed, and 750l of diluent
reagent (provided) was added to resuspend the cell pellet. Samples were
vortexed for 5 min to liberate nucleic acid, and a 5-l portion of the lysate
was added to a master mix tube along with 21l of diluent to reconstitute
lyophilized PCR reagents. A 25-l portion of the reaction components
(mixed master plus specimen) was transferred to a SmartTube and tested
using the SmartCycler DX system, following the recommended thermo-
cycling parameters for the Smart GBS assay. A positive control and a
negative control were included with each Smart GBS run. In addition, the
Smart GBS assay includes an internal control to confirm the proper am-
plification in each real-time PCR. Specimens are reported as positive or
negative based on the parameters set in the SmartCycler protocol. Invalid
results were repeated once using residual specimen lysates.
Broth-enriched cultures for identificationofGBS.As a gold standard
in this study, one of two paired swabs was inoculated into LIM broth for
16 to 24 h at 35 to 37°C. The broth-enriched cultures were subcultured to
BAP and incubated at 35 to 37°C for up to 48 h. The broth-enriched
subcultures were examined for the presence of beta-hemolytic colonies as
a presumptive identification of GBS. The identification was confirmed
using a Gram stain (Gram-positive cocci in chains), catalase (nonreac-
tive), and a group B Streptococcus latex agglutination test (Streptex; Remel,
Lenexa, KS).
Discrepant result analysis. A discrepant result was defined as a result
obtained with the Xpert GBS, Xpert GBS LB, or Smart GBS assay that did
not correlate with the culture results. The molecular test-positive, culture-
negative or molecular test-negative, culture-positive discrepant results
were resolved using bidirectional sequence analysis of the GBS cfp target
with primers different from those used for the Xpert GBS and Smart GBS
assays.
Statistical analysis.The results from the Xpert GBS LB and Smart GBS
assay were compared to culture results as a gold standard. The perfor-
mance characteristics, including sensitivity and specificity, were calcu-
lated using standard methods. The 95% confidence intervals (CI) were
calculated by using a binomial expansion.
RESULTS
Comparison of Xpert GBS LB assay to enriched culture. A total
of 861 subjects were enrolled at three clinical centers to test the
ability of the Xpert GBS LB assay to detect GBS from broth-en-
riched cultures. Thirty-five specimens were excluded from the
analysis due to failure in meeting the predetermined inclusion
criteria. These included 11 (1.2% of total samples tested) speci-
mens with LIM broth inoculated24 h after swab collection, 11
(1.2%) specimens with LIM broth incubated 24 h, 8 (0.9%)
specimens without broth enrichment culture, 2 (0.2%) specimens
tested using incorrect or expired Xpert test cartridges, 2 (0.2%)
mislabeled cultures, and 1 (0.1%) specimen without a reference
culture result. This reduced the total number of protocol-compli-
ant specimens to 826, which were used to generate performance
data. Compared to the reference method, the sensitivities of the
Xpert GBS LB assay at the three clinical sites were 98.6% (73/74),
97.8% (44/45), and 100% (72/72) (Table 1). Combined, these data
resulted in 99.0% overall sensitivity (189/191) with a 95% CI of
95.9% to 99.8%. Sequence analysis of the two false-negative re-
sults failed to identify GBS.
A total of 48 culture-negative, Xpert GBS LB assay-positive
specimens were identified at the three clinical sites, resulting in an
overall specificity of 92.4% (587/635). Two clinical centers found
similar specificities of 94.1% and 95.4%, while the third center
reported a lower specificity of 88.2%. Of the 48 false-positive re-
sults, 47 (97.9%) were available for discrepant analysis using nu-
cleic acid sequencing. The sequence analysis confirmed the pres-
ence of GBS in 89.4% (42/47) of the discrepant specimens
analyzed. Further, 24/47 were also positive when tested using the
Smart GBS assay. These findings support the presence of GBS
nucleic acid within these specimens and raise the combined spec-
ificity of Xpert GBS LB assay to 99.2% (629/634) for evaluable
specimens. The remaining specimen was unavailable for discrep-
ant analysis.
Direct testing of swab specimens using the Xpert GBS assay.
Two of the three clinical sites compared the ability to detect GBS
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directly from swab specimens to detection following broth enrich-
ment using the Xpert GBS and Xpert GBS LB assays, respectively.
A total of 505 enrolled subjects were available for direct testing,
and the results were compared to those for the reference culture.
The sensitivity of direct testing was 85.7% (96/112) overall, with
sensitivities of 82.9% (34/41) and 87.3% (62/71) reported at indi-
vidual sites (Table 2). The specificity was determined to be 96.2%
(378/393) overall, with 98.1% (153/156) for one site and 94.9%
(225/237) for the second site. This is in comparison to a combined
99.1% (116/117) sensitivity for broth-enriched cultures tested at
these two sites. These data indicate a statistically significant (P
0.001) decrease in sensitivity for testing of direct (swab) specimens
compared to that for testing conducted after broth enrichment.
Comparison of Xpert GBS LB assay to Smart GBS assay for
detection of GBS from broth-enriched culture. Broth-enriched
swab specimens tested using the Xpert GBS LB assay were also
tested using another FDA-cleared molecular test, the Smart GBS
assay, for detection of GBS. Twelve specimens could not be tested
in accordance with the Smart GBS package insert and were ex-
cluded from analysis. Compared to reference culture methods, the
sensitivity and specificity of the Smart GBS assay were 96.8% (184/
190) and 95.5% (595/623), respectively (Table 3).
Three of the six specimens categorized as false negative based
on the Smart GBS result were available for sequence analysis. Two
of these specimens were found to be positive for the presence of
GBS nucleic acid, while the other one was negative. The remaining
3 specimens were not available for discrepant analysis. For the
sequence analysis of 26 specimens categorized as resolved, 24/26
were positive for GBS and 2/26 were negative. Two specimens
categorized as false positive were not available for discrepant anal-
ysis. These data support the presence or absence of GBS nucleic
acid in these specimens and raise the combined sensitivity and
specificity to 99.0% and 99.6%, respectively, for the Smart GBS
assay.
XpertGBSLBassay analytical success rate.The Xpert GBS LB
assay had an initial test success rate of 98.1% (810/826). The in-
determinate cases included 12 error results, 2 invalid results, and 2
no result outcomes. All indeterminate specimens were retested
and yielded valid results upon a single retest, raising the final suc-
cess rate to 100%. The direct testing of swabs resulted in an initial
test success rate of 90.6% (471/520). A single retest of the initially
unresolved specimens resulted in 34/48 valid results, giving a final
call rate for direct testing of 97.1% (505/520). The test for one
specimen with an initial invalid result could not be repeated. Of
note, there was a significant difference in the direct testing success
rates between the two sites. Site B had an initial test success rate of
78.3% (166/212), while site C had an initial test success rate of
99.0% (305/308). Site B received specimens from 14 clinic sites.
The error/invalid rate for specimens received from these sites var-
ied from 0% to 57%, suggesting that variance in specimen collec-
tion practices by specific providers or clinics (such as the use/
amount of lubricant or other material used during collection of
the specimens) may impact the assay call rate. Unfortunately, be-
cause of the deidentified nature of the specimens, we were not able
to further investigate this hypothesis. Alternatively, the low initial
success rate observed at site B may be related to the training and
familiarity of the staff with the assay. Site C routinely uses the
Xpert GBS assay for the direct analysis of swab specimens as a
standard of care while site B does not routinely use this assay.
Other publications have noted that the rates of invalid results
decrease over time as sites gain experience with the assay (15).
DISCUSSION
The implementation of universal screening of pregnant women at
35 to 37 weeks’ gestation has significantly reduced the risk of early-
onset GBS infection in neonates from 1.5 per 1,000 births in the
1980s to 0.34 per 1,000 births in recent years (4, 5). Several studies
have been performed to identify the cause of the remaining infec-
tions. A major contributing factor is the failure to seek prenatal
care, including routine GBS screening, which affects up to 15% of
TABLE 2 Performance of the Xpert GBS assay for analysis of direct swab specimens compared to broth-enriched culture
Clinical test
site
No. of specimens
at site
No. of specimens with result of:
Sensitivity (% [CI]) Specificity (% [CI])TP TN FP FN
B 197 34 153 3 7 82.9 (67–92) 98.0 (94–100)
C 308 62 225 12 9 87.3 (77–94) 94.9 (91–97)
Total 505 96 378 15 16 85.7 (78–91) 96.2 (94–98)
TABLE 1 Performance of the Xpert GBS LB assay for analysis of LIM broth-enriched specimens compared to broth-enriched culture
Clinical test
site
No. of specimens
at site
No. of specimens with result of:a
Sensitivity (% [CI])b Specificity (% [CI])TP TN FP FN
A 295 73 195 26 1 98.6 (92–99) 88.2 (83–92)
B 220 44 167 8 1 97.8 (87–100) 95.4 (91–98)
C 311 72 225 14 0 100 (934–100) 94.1 (90–97)
Total 826 189 587 48c 2d 99.0 (96–100) 92.4 (90–94)
a TP, true positive; TN, true negative; FP, false positive; FN, false negative.
b CI, 95% confidence interval.
c Forty-two of 47 specimens were confirmed as positive for GBS and 5/47 as negative for GBS following discrepant analysis by nucleic acid sequencing. Additionally, 24/47
specimens were positive when tested with the Smart GBS assay. One specimen was not available for discrepant analysis.
d Both specimens were confirmed as negative for GBS following discrepant analysis by nucleic acid sequencing.
Detection of S. agalactiae Using Xpert GBS LB Assay
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all pregnant women (16). Another complicating factor is that
women may be colonized in the days or weeks between the time of
the routine GBS screening and delivery. In these cases, the neonate
is at risk of infection despite the negative screen result (17, 18).
One study has shown that 70% of early-onset neonatal GBS
infections are associated with mothers whose colonization status
was either unknown or negative at the time of screening (35 to 37
weeks’ gestation) (17). In these instances, use of a rapid method
for the detection of GBS at the time of delivery may help deter-
mine if the administration of prophylaxis during delivery is war-
ranted (16).
This multicenter clinical evaluation of the Xpert GBS LB assay
for the identification of GBS included a total of 826 samples that
were qualified for the established study criteria. The overall prev-
alence of GBS colonization was 23.1% (ranging from 20.4 to
25.0%) as determined by the LIM broth-enriched culture method.
The Xpert GBS LB assay was more sensitive than the culture
method as demonstrated by the identification of 42 specimens
that were positive by the Xpert GBS assay but negative by the
combined culture methods. The additional 42 GBS-positive spec-
imens identified by the Xpert GBS LB assay may be attributable to
a low concentration of GBS in the specimen which was not recov-
ered by culture or to the identification of non-beta-hemolytic GBS
that were missed by culture. Previous studies have demonstrated
decreased recovery of GBS following broth enrichment of speci-
mens containing a high concentration of Enterococcus spp., which
overgrow GBS in broth and hinder recovery upon subculture (19,
20). Alternatively, these additional positive results might corre-
spond to a nonviable organism or a residual GBS nucleic acid in
the specimen from previous carriage. It is unlikely that these re-
sults were due to template or amplicon contamination of the
Xpert LB test since 42/47 (89.4%) of specimens resolved using
nucleic acid sequencing were found to be positive for GBS. The
Xpert GBS LB assay also demonstrated increased sensitivity com-
pared to that of the Smart GBS assay (99.0% [CI, 96.3% to 99.9%]
and 96.8% [CI, 93.3% to 98.8%], respectively (Table 3); however,
this difference was not statistically significant (P  0.15). The
specificity of the Xpert GBS LB assay was lower than that of the
Smart GBS assay (92.4% compared to 95.5%); however, this dif-
ference was also not statistically significant.
Direct testing from the collection swab demonstrated a re-
duced sensitivity of 85.7% compared to those of the two broth-
enriched molecular methods. Other studies that have compared
the Xpert GBS assay to culture have found sensitivities ranging
from 91.0% to 99.6% (21, 22). In one study, a selective medium
was used, and in another, any nonhemolytic colonies that had
similar colony morphology of GBS were further characterized.
These differences might explain the difference in sensitivities be-
tween studies because the comparison assays were more sensitive
than BAP alone. Although results are significantly less sensitive
than those for enriched specimens, the ability to test a direct spec-
imen may aid in guiding administration of prophylaxis in the 10 to
15% of patients who have not been screened prior to delivery, in
cases of unexpected or early labor where enrichment culture re-
sults are not yet available, or as a method for identifying women
who were colonized between routine screening and time of deliv-
ery. A number of studies suggest, through indirect observation,
that low-level carriage of GBS is associated with a reduced trans-
mission rate compared to that in patients with higher bacterial
burdens (23–25). In these cases, a rapid, direct molecular test
would likely identify those women most at risk of transmission of
GBS to the neonate despite the reduced sensitivity compared to
that of testing of enriched cultures. Challenges other than the lim-
its of detection (LOD) can also affect the ability to test primary
swab specimens using PCR. These include the presence of mucus
or lubricant in a specimen, variable specimen viscosities, or the
presence of blood or other materials that can physically interfere
with the microfluidics of an assay such as the Xpert GBS or directly
inhibit PCRs. The current protocol for direct swab testing does
not involve any processing of the sample that might help in over-
coming these barriers such as the dilution or filtration of speci-
mens. This, combined with user variability, may explain the high
indeterminate result rate observed at one test site during direct
testing with the Xpert GBS assay.
A strength of this study is the large number of tested samples
(n  826) along with the collection and testing of specimens at
three separate sites. The statistically equivalent performance of the
Xpert GBS LB assay at three separate sites (sensitivity of 97.8% to
100% and specificity of 88.2% to 95.4%) demonstrates that the
assay is a reliable diagnostic device, independent of external vari-
ables such as laboratory personnel, laboratory workflow, and
specimen collection practices. An advantage of the Xpert GBS LB
and Xpert GBS assays is the sample-to-result capability. Com-
pared to the Smart GBS assay, this moderate complexity setup of
the assay allows for minimal hands-on time, requiring2 min per
sample. In addition, specimen lysis, nucleic acid extraction, target
amplification, and detection are performed within the test car-
tridge. This automation reduces the chance of contamination dur-
ing handling and reduces the time to the result compared to those
of other molecular tests that rely on manual specimen processing
and setup of multiple real-time PCRs.
A commonly cited drawback of incorporation of molecular
TABLE 3 Comparison of the Smart GBS and Xpert GBS LB assays to the broth-enriched culture
Test
No. of
specimens
No. of specimens with result of:
Sensitivity (% [CI]) Specificity (% [CI])TP TN FP FN
Smart GBS 813 184 595 28a 6b 96.8 (93–99) 95.5 (94–97)
Xpert GBS LB 826 189 587 48c 2d 99.0 (96–100) 92.4 (90–94)
a Twenty-four of 26 specimens were confirmed as positive for GBS and 2/26 as negative for GBS following discrepant analysis by nucleic acid sequencing. Two specimens were not
available for discrepant analysis.
b Two of 3 specimens were confirmed as positive for GBS and 1/3 as negative following discrepant analysis by nucleic acid sequencing. The remaining 3 were not available for
discrepant analysis.
c Forty-two of 47 specimens were confirmed as positive for GBS and 5/47 as negative following discrepant analysis by nucleic acid sequencing. Additionally, 24/47 were positive
when tested with the Smart GBS assay. One specimen was not available for discrepant analysis.
d Both specimens were confirmed as negative for GBS following discrepant analysis by nucleic acid sequencing.
Buchan et al.
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tests for routine GBS screening is the higher cost than that of
bacterial culture methods (26). Because screening for GBS colo-
nization generally takes place 3 to 5 weeks prior to delivery under
the current guidelines, rapid detection is not routinely necessary
and may not justify the increased cost for molecular detection. A
study by Berg et al. compared five different approaches for detect-
ing GBS from vaginal/rectal swabs at 35 to 37 weeks’ gestation,
including Northeast Laboratory GBS agar (Northeast Laboratory
Services, Winslow, ME), GBS Detect (Hardy Diagnostics, Santa
Maria, CA), and GBS PCR from enriched LIM and carrot broth
cultures (27). The researchers demonstrated that enriched PCR
methods could yield quicker results, but there was no significant
improvement in GBS detection. In addition, the cost of reagents
and labor was 13 times more for PCR detection than for the use of
chromogenic media. The use of matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF MS)
for identification of bacterial and fungal isolates has been shown
to cost less than $1 per specimen and reduces the overall cost of
identification by approximately 57% (28, 29). However, this tech-
nology currently requires a pure bacterial isolate, which renders it
inapplicable for identification of GBS in enrichment broth.
Although the additional cost of PCR-based identification of
GBS may not be efficient for screening at 35 to 37 weeks’ gestation,
two recent studies have demonstrated a cost benefit of implement-
ing molecular testing at the time of delivery. One study performed
a cost-effectiveness analysis comparing the current 35 to 37 weeks’
screening to PCR screening at the time of delivery (17). This study
estimated that the current screening method resulted in unneces-
sary antibiotic prophylaxis for 13.6% of pregnant women in the
study compared to 4.5% for women using the intrapartum PCR
test. This resulted in incremental costs of €36 and €173 to the
health care system and hospital, respectively, for each misman-
aged patient. Furthermore, the overuse of antibiotics in 13.6% of
all patients may lead to antibiotic-resistant strains. The current
studies have not identified significant penicillin resistance, but
depending on the region, 10 to 38% and 5.0 to 51% of isolated
GBS have resistance to erythromycin and clindamycin, respec-
tively (30, 31). A second study found that PCR screening during
pregnancy would be cost neutral and may result in an overall
reduction in early-onset GBS disease (32). A small reduction in
the incidence of early-onset GBS disease based on the use of a
molecular test might also justify the additional cost because, on
average, the cost of an early-onset GBS infection is€19,000, and
infants who survive incur health care and social care costs twice as
high as those for unaffected infants (33).
The results of this study support the increased sensitivity of
molecular testing and add to the literature further evidence that
the use of molecular methods for the detection of GBS coloniza-
tion might increase the number of recognized carriers, which may
further reduce the rate of early-onset GBS infection.
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